Antithrombotic management in patients undergoing cardiac implantable electronic device implantation

Cardiac implantable electronic devices (CIEDs) are an established treatment option for arrhythmias, sudden cardiac death prevention, and heart failure. Approximately 1000 implanted per million inhabitants in European countries each year. However, the main concern patients with indication CIED implantation is frequently associated comorbidities requiring antithrombotic medications. The invasive device procedure represents a bleeding risk ranging from pocket hematoma to tamponade. On other hand, temporary interruption of therapy increases thromboembolic events. Implanting CIEDs on medications incites several clinical dilemmas balancing against risk, as complications higher mortality rates both aspects. most common complication haematoma formation, which prolonged hospital stay, cost, infection, thus morbidity mortality. Studies have shown that heparin bridging strategy oral anticoagulants imposes greater formation no benefit reducing Most procedures can be performed safely uninterrupted anticoagulants. Dual antiplatelet should avoided whenever possible.